ECSP22085947A - Derivados de 4-(2,6-difluorofenoxi)-6-(trifluorometil)pirimidin-2-amina como potenciadores del receptor hmrgx1 para el tratamiento del dolor - Google Patents

Derivados de 4-(2,6-difluorofenoxi)-6-(trifluorometil)pirimidin-2-amina como potenciadores del receptor hmrgx1 para el tratamiento del dolor

Info

Publication number
ECSP22085947A
ECSP22085947A ECSENADI202285947A ECDI202285947A ECSP22085947A EC SP22085947 A ECSP22085947 A EC SP22085947A EC SENADI202285947 A ECSENADI202285947 A EC SENADI202285947A EC DI202285947 A ECDI202285947 A EC DI202285947A EC SP22085947 A ECSP22085947 A EC SP22085947A
Authority
EC
Ecuador
Prior art keywords
pain
hmrgx1
difluorophenoxy
pyrimidine
trifluoromethyl
Prior art date
Application number
ECSENADI202285947A
Other languages
English (en)
Inventor
Daryl Lynn Smith
Leonard Larry Winneroski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP22085947A publication Critical patent/ECSP22085947A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de la Fórmula I: en donde R1 es hidrógeno o metilo; y R2 es: o una sal aceptable desde el punto de vista farmacéutico de este, útil para tratar el dolor, que incluye dolor crónico, dolor lumbar crónico, dolor neuropático periférico diabético y dolor por osteoartritis.
ECSENADI202285947A 2020-05-08 2022-11-08 Derivados de 4-(2,6-difluorofenoxi)-6-(trifluorometil)pirimidin-2-amina como potenciadores del receptor hmrgx1 para el tratamiento del dolor ECSP22085947A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063021806P 2020-05-08 2020-05-08

Publications (1)

Publication Number Publication Date
ECSP22085947A true ECSP22085947A (es) 2022-12-30

Family

ID=76012049

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202285947A ECSP22085947A (es) 2020-05-08 2022-11-08 Derivados de 4-(2,6-difluorofenoxi)-6-(trifluorometil)pirimidin-2-amina como potenciadores del receptor hmrgx1 para el tratamiento del dolor

Country Status (18)

Country Link
US (2) US11414389B2 (es)
EP (1) EP4146630B1 (es)
JP (1) JP7407971B2 (es)
KR (1) KR20230006563A (es)
CN (1) CN115803321A (es)
AR (1) AR122450A1 (es)
AU (1) AU2021268887B2 (es)
BR (1) BR112022022366A2 (es)
CA (1) CA3178068A1 (es)
CL (1) CL2022003097A1 (es)
CO (1) CO2022016014A2 (es)
CR (1) CR20220568A (es)
EC (1) ECSP22085947A (es)
IL (1) IL297974A (es)
MX (1) MX2022013982A (es)
PE (1) PE20231065A1 (es)
TW (1) TWI782504B (es)
WO (1) WO2021225878A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR122450A1 (es) * 2020-05-08 2022-09-14 Lilly Co Eli Compuestos de (trifluorometil)pirimidin-2-amina
CA3236382A1 (en) * 2021-11-08 2023-05-11 James Craig Ruble Deuterated (trifluoromethyl)pyrimidine-2-amine compounds as potentiators of the hmrgx1 receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637697A (en) * 1965-11-01 1972-01-25 Upjohn Co 6-amino-1 2-dihydro-1-hydroxy-2-iminopyrimidines
DE3842177A1 (de) 1988-12-15 1990-06-21 Basf Ag Substituierte sulfonylharnstoffe
DE19608831A1 (de) 1996-03-07 1997-09-18 Bayer Ag Substituierte Thienylsulfonyl(thio)harnstoffe
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
GB0021494D0 (en) * 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
EP1648876A1 (en) * 2003-07-24 2006-04-26 Pharmagene Laboratories Ltd 5-ht sb 2b /sb receptor antagonists
WO2008052072A2 (en) * 2006-10-24 2008-05-02 Acadia Pharmaceuticals Inc. Compounds for the treatment of pain and screening methods therefor
EP3205647B1 (en) 2009-08-17 2020-05-13 Memorial Sloan-Kettering Cancer Center 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders
EP3495359A1 (en) 2013-02-04 2019-06-12 Janssen Pharmaceutica NV Flap modulators
AR122450A1 (es) * 2020-05-08 2022-09-14 Lilly Co Eli Compuestos de (trifluorometil)pirimidin-2-amina

Also Published As

Publication number Publication date
KR20230006563A (ko) 2023-01-10
US20210347738A1 (en) 2021-11-11
CO2022016014A2 (es) 2022-11-29
EP4146630A1 (en) 2023-03-15
PE20231065A1 (es) 2023-07-12
TWI782504B (zh) 2022-11-01
WO2021225878A1 (en) 2021-11-11
AU2021268887B2 (en) 2024-04-04
JP2023524817A (ja) 2023-06-13
EP4146630B1 (en) 2024-04-24
MX2022013982A (es) 2022-11-30
TW202208340A (zh) 2022-03-01
AU2021268887A1 (en) 2022-12-08
CR20220568A (es) 2022-12-07
US11773067B2 (en) 2023-10-03
JP7407971B2 (ja) 2024-01-04
CN115803321A (zh) 2023-03-14
IL297974A (en) 2023-01-01
BR112022022366A2 (pt) 2022-12-13
CA3178068A1 (en) 2021-11-11
AR122450A1 (es) 2022-09-14
US20220372003A1 (en) 2022-11-24
CL2022003097A1 (es) 2023-06-16
US11414389B2 (en) 2022-08-16

Similar Documents

Publication Publication Date Title
ECSP22085947A (es) Derivados de 4-(2,6-difluorofenoxi)-6-(trifluorometil)pirimidin-2-amina como potenciadores del receptor hmrgx1 para el tratamiento del dolor
UY39029A (es) Uso de compuestos de aminopropionato sustituido en el tratamiento de la infección por sars-cov-2
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
PE20081796A1 (es) Derivados de pirimidina
PE20160524A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
CL2022002813A1 (es) Semaglutida para el tratamiento de esteatohepatitis no alcoholica.
PE20061163A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
EA200801001A1 (ru) Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
PE20060240A1 (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
PE20140966A1 (es) Quinazolincarboxamida azetidinas
UY32131A (es) Compuestos de anillo fusionado y uso de los mismos
PE20090798A1 (es) Derivados de benzotiazol como moduladores del receptor de grelina
CR20200522A (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
DOP2019000076A (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
CO2022015930A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
BR112023025599A2 (pt) Ativadores de dimetoxifenilalquilamina de receptores de serotonina.
CO2022015927A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso
PE20221517A1 (es) Derivado de triazolopiridazina, metodo de preparacion del mismo, composicion farmaceutica del mismo y uso del mismo
PE20091086A1 (es) Compuestos que potencian el receptor de ampa y usos de los mismos en medicina